{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:51:15Z","timestamp":1790927475114,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PubMed, Embase, and Cochrane Library databases were systematically searched for epidemiological studies reporting the prevalence of SAPH up to July 2021. Two reviewers independently performed the study selection, data extraction, and quality assessment. Studies were pooled using random-effects meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis included 25 high-quality studies from 12 countries, with a pooled sample of 632,368 patients with sarcoidosis. The prevalence of SAPH by transthoracic echocardiography in Europe, the United States and Asia was 18.8% [95% confidence interval (CI): 11.1\u201326.5%], 13.9% (95% CI: 5.4\u201322.4%) and 16.2% (95% CI: 7.1\u201325.4%) separately, and the overall pooled prevalence was 16.4% (95%CI: 12.2\u201320.5%). By right heart catheterization (RHC), the pooled prevalence of SAPH was 6.4% (95% CI: 3.6\u20139.1%) in general sarcoidosis population, and subgroup analyses showed that the prevalence of SAPH was 6.7% (95% CI: 2.4\u201311.0%) in Europe and 8.6% (95% CI: \u22124.1 to 21.3%) in the United States. Further, the prevalence of pre-capillary PH was 6.5% (95% CI: 2.9\u201310.2%). For the population with advanced sarcoidosis, the pooled prevalence of SAPH and pre-capillary PH by RHC was as high as 62.3% (95% CI: 46.9\u201377.6%) and 55.9% (95% CI: 20.1\u201391.7%), respectively. Finally, the pooled prevalence of SAPH in large databases with documented diagnoses (6.1%, 95% CI: 2.6\u20139.5%) was similar to that of RHC. Substantial heterogeneity across studies was observed for all analyses (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> &amp;gt; 80%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The sarcoidosis population has a relatively low burden of PH, mainly pre-capillary PH. However, as the disease progresses to advanced sarcoidosis, the prevalence of SAPH increases significantly.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2021.809594","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T05:17:55Z","timestamp":1642396675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Shijie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"P9","DOI":"10.1164\/rccm.1976P9","article-title":"Treatment of sarcoidosis","volume":"197","author":"Raghu","year":"2018","journal-title":"Am J Resp Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"106564","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study","volume":"187","author":"Zhou","year":"2021","journal-title":"Respir Med."},{"key":"B3","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1183\/09031936.00175511","article-title":"Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation","volume":"39","author":"Shlobin","year":"2012","journal-title":"Eur Respir J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): Endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1700465","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur Respir J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1378\/chest.09-2002","article-title":"Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation","volume":"138","author":"Baughman","year":"2010","journal-title":"Chest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1902223","DOI":"10.1183\/13993003.02223-2019","article-title":"Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies","volume":"55","author":"Pabst","year":"2020","journal-title":"Eur Respir J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/MCP.0000000000000793","article-title":"Sarcoidosis associated pulmonary hypertension","volume":"27","author":"Samaranayake","year":"2021","journal-title":"Curr Opin Pulm Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J Clin Epidemiol."},{"key":"B19","unstructured":"HigginsJ\n            GreenS\n          34160443Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.2011"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1900897","DOI":"10.1183\/13993003.00897-2019","article-title":"Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study","volume":"54","author":"Huitema","year":"2019","journal-title":"Eur Respir J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.healun.2007.11.576","article-title":"Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?","volume":"27","author":"Milman","year":"2008","journal-title":"J Heart Lung Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.4081\/monaldi.2021.1636","article-title":"Sarcoidosis at the pulmonary medicine department of a tertiary care hospital in Mumbai. Our experience and the new modified criteria clinical radiological physiological (TNMC CRP) score for sarcoidosis: a novel proposition to assess the functional status","volume":"91","author":"Utpat","year":"2021","journal-title":"Monaldi Arch Chest Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14744\/AnatolJCardiol.2020.88054","article-title":"Pulmonary hypertension in patients with sarcoidosis: a single-center experience","volume":"25","author":"Kaptan Ozen","year":"2021","journal-title":"Anatol J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s10554-020-01859-9","article-title":"Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography","volume":"36","author":"Huitema","year":"2020","journal-title":"Int J Cardiovasc Imag."},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clim.2018.12.012","article-title":"The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - a cohort study","volume":"199","author":"Tiosano","year":"2019","journal-title":"Clin Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e15779","DOI":"10.1097\/MD.0000000000015779","article-title":"Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015","volume":"98","author":"Pedraza-Serrano","year":"2019","journal-title":"Medicine."},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","article-title":"Mortality for sarcoidosis patients on the transplant wait list in the lung allocation score era: experience from a high volume center","volume":"157","author":"Gangemi","year":"2019","journal-title":"Respir Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.rmed.2019.04.009","article-title":"Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care","volume":"152","author":"Frank","year":"2019","journal-title":"Respir Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e007844","DOI":"10.1161\/JAHA.117.007844","article-title":"Hospitalization rates, prevalence of cardiovascular manifestations, and outcomes associated with sarcoidosis in the United States","volume":"7","author":"Patel","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ehf2.12166","article-title":"Right ventricular involvement in cardiac sarcoidosis demonstrated with cardiac magnetic resonance","volume":"4","author":"Smedema","year":"2017","journal-title":"ESC Heart Fail."},{"key":"B31","first-page":"317","article-title":"The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis","volume":"33","author":"Mirsaeidi","year":"2016","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1183\/13993003.01319-2015","article-title":"Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis","volume":"47","author":"Huitema","year":"2016","journal-title":"Eur Respir J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00408-012-9442-4","article-title":"Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors","volume":"191","author":"Rapti","year":"2013","journal-title":"Lung."},{"key":"B34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-94-007-4546-9_38","article-title":"Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience","volume":"755","author":"Pabst","year":"2013","journal-title":"Adv Exp Med Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"406","DOI":"10.5588\/ijtld.12.0428","article-title":"Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function","volume":"17","author":"Maimon","year":"2013","journal-title":"Int J Tuberc Lung Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/1817-1737.62471","article-title":"Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients","volume":"5","author":"Alhamad","year":"2010","journal-title":"Ann Thorac Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1752-699X.2008.00120.x","article-title":"Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil","volume":"3","author":"Milman","year":"2009","journal-title":"Clin Respir J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1183\/09031936.00175907","article-title":"Clinical predictors of pulmonary hypertension in sarcoidosis","volume":"32","author":"Bourbonnais","year":"2008","journal-title":"Eur Respir J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1378\/chest.06-2822","article-title":"Six-minute walk test and health status assessment in sarcoidosis","volume":"132","author":"Baughman","year":"2007","journal-title":"Chest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","article-title":"Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis","volume":"129","author":"Handa","year":"2006","journal-title":"Chest."},{"key":"B41","first-page":"108","article-title":"Pulmonary hypertension in sarcoidosis","volume":"23","author":"Baughman","year":"2006","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1378\/chest.128.3.1483","article-title":"Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension","volume":"128","author":"Sulica","year":"2005","journal-title":"Chest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1183\/09031936.05.00083404","article-title":"Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics","volume":"25","author":"Shorr","year":"2005","journal-title":"Eur Respir J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"eabi8020","DOI":"10.1126\/sciadv.abi8020","article-title":"Predicting risk of sudden cardiac death in patients with cardiac sarcoidosis using multimodality imaging and personalized heart modeling in a multivariable classifier","volume":"7","author":"Shade","year":"2021","journal-title":"Sci Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"100936","DOI":"10.1016\/j.cpcardiol.2021.100936","article-title":"Cardiac sarcoidosis: a clinical overview","volume":"46","author":"Alba","year":"2021","journal-title":"Curr Prob Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/thx.2005.042838","article-title":"Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis","volume":"61","author":"Nunes","year":"2006","journal-title":"Thorax."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/0046-8177(92)90288-E","article-title":"Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases","volume":"23","author":"Takemura","year":"1992","journal-title":"Human Pathol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"190168","DOI":"10.1183\/16000617.0168-2019","article-title":"Pulmonary capillary haemangiomatosis: a distinct entity?","volume":"29","author":"Weatherald","year":"2020","journal-title":"Eur Res Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.resinv.2016.05.005","article-title":"An autopsy case of refractory pulmonary hypertension with sarcoidosis","volume":"54","author":"Ota","year":"2016","journal-title":"Res Inv."},{"key":"B50","first-page":"809","article-title":"Sarcoidosis simulating pulmonary veno-occlusive disease","volume":"134","author":"Hoffstein","year":"1986","journal-title":"Am Rev Res Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.chest.2016.09.009","article-title":"Association of sarcoidosis with increased risk of VTE: a population-based study, 1976 to 2013","volume":"151","author":"Ungprasert","year":"2017","journal-title":"Chest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.5114\/ceji.2015.56972","article-title":"Venous thromboembolism and sarcoidosis: co-incidence or coexistence?","volume":"40","author":"Goljan-Geremek","year":"2015","journal-title":"Cent Eur J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1378\/chest.11-0324","article-title":"Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007","volume":"140","author":"Swigris","year":"2011","journal-title":"Chest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/CPM.0000000000000252","article-title":"Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment","volume":"25","author":"Duong","year":"2018","journal-title":"Clin Pulm Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.36141\/svdld.v36i4.8606","article-title":"The frequency of diastolic dysfunction in patients with sarcoidosis and it's relationship with HLA DRB1* alleles","volume":"36","author":"Ozyilmaz","year":"2019","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1378\/chest.15-0584","article-title":"Interrelationship between sleep-disordered breathing and sarcoidosis","volume":"148","author":"Lal","year":"2015","journal-title":"Chest."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S0012-3692(15)37649-2","article-title":"Predicting mortality in patients with sarcoidosis awaiting lung transplantation","volume":"124","author":"Shorr","year":"2003","journal-title":"Chest."},{"key":"B59","first-page":"525","article-title":"Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients","volume":"52","author":"Neville","year":"1983","journal-title":"Quart J Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/ehjci\/ehaa946.2231","article-title":"Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series","volume":"37","author":"Mathijssen","year":"2020","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B61","first-page":"82","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies","volume":"31","author":"Keir","year":"2014","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest."},{"key":"B63","first-page":"110","article-title":"Inhaled iloprost for sarcoidosis associated pulmonary hypertension","volume":"26","author":"Baughman","year":"2009","journal-title":"Sarcoid Vasc Diffuse Lung Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1378\/chest.130.5.1481","article-title":"Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment","volume":"130","author":"Fisher","year":"2006","journal-title":"Chest."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2021.2161","article-title":"Global prevalence of young-onset dementia: a systematic review and meta-analysis","volume":"78","author":"Hendriks","year":"2021","journal-title":"JAMA Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0223599","DOI":"10.1371\/journal.pone.0223599","article-title":"Prevalence of methicillin-resistant staphylococcus aureus in healthy Chinese population: a system review and meta-analysis","volume":"14","author":"Wu","year":"2019","journal-title":"PLoS ONE."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.809594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T05:18:03Z","timestamp":1642396683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.809594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":66,"alternative-id":["10.3389\/fcvm.2021.809594"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.809594","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"809594"}}